Morgan Stanley raises target for BeOne Medicines stock to USD 425.00

Published on 10/20/2026 at 19:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

ESMO 2026 runs October 23-27 in Madrid with 12 BeOne abstracts. BeOne Medicines stock costs EUR 339.00 on October 20, 2026 at 7:32 p.m. CEST.

Analyst target and reporting date

Morgan Stanley raised its BeOne Medicines target from USD 405.00 to USD 425.00 on October 16, 2026.
BeOne Medicines will present 12 abstracts at ESMO 2026 from October 23 to October 27.
BeOne Medicines stock costs EUR 339.00 at Lang & Schwarz on October 20, 2026 at 7:32 p.m. CEST.
The company reported USD 1.71 billion in second-quarter 2026 revenue, up 30.00 percent year over year.

ONC, US07725L1026, Illustration mit AI erstellt.

BeOne Medicines raised its investor profile ahead of ESMO 2026 after Morgan Stanley analyst Sean Laaman lifted the price target from USD 405.00 to USD 425.00 on October 16, 2026, according to Markets Insider. BeOne Medicines stock was trading at EUR 339.00 at Lang & Schwarz on October 20, 2026 at 7:32 p.m. CEST.

Target points to 11.36 percent upside

The Morgan Stanley target stands 11.36 percent above the Nasdaq quote of USD 381.64 at 1:35 p.m. ET on October 20, 2026. The firm kept its Overweight rating and linked its view to the upcoming ESMO presentations, according to Markets Insider.

ESMO brings 12 abstracts

BeOne Medicines said on October 19, 2026 that it will present data from its solid-tumor portfolio at ESMO 2026 in Madrid from October 23 to October 27. The program includes studies of GPC3x4-1BB, a CEA antibody-drug conjugate, a CDK4 inhibitor and a PRMT5 inhibitor, according to Business Wire.

Revenue growth supports valuation

In the second quarter of 2026, revenue reached USD 1.71 billion, up 30.00 percent from the prior-year quarter, while GAAP earnings per ADS rose to USD 2.05 from USD 0.84. The company also raised its 2026 revenue outlook by USD 300 million to USD 6.60 billion-USD 6.80 billion, according to its earnings-call transcript carried by Yahoo Finance. The quarter included a USD 60 million tax audit settlement impact on reported results.

Comparison with peers

BeOne Medicines: up 3.10 percent, P/E 27.21, market capitalization USD 40.8 billion. Bristol-Myers Squibb (NYSE, USD): up 4.59 percent, P/E 13.55, market capitalization USD 125.7 billion. Regeneron Pharmaceuticals (Nasdaq, USD): up 1.88 percent, P/E 19.69, market capitalization USD 82.0 billion. These market figures are dated October 20, 2026.

Price and upcoming dates

The next immediate corporate date is the ESMO program from October 23 to October 27, 2026. Investors will also receive BeOne Medicines' next financial update in November 2026, as stated during the second-quarter earnings call.

Stock position

BeOne Medicines stock was trading at EUR 339.00 at Lang & Schwarz on October 20, 2026 at 7:32 p.m. CEST. On Nasdaq, the stock was last quoted at USD 381.64 on October 20, 2026 at 1:35 p.m. ET.

The further course of trading is shown by the continuously updated real-time quote of BeOne Medicines stock.